ALPHAMAB-B(09966),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

09966 ALPHAMAB-B

Market Closed 12-19 16:08:06

10.910

+0.240

+2.25%

High11.200	Low10.450	Vol2.00M
Open10.700	D1 Closing10.670	Amplitude7.03%
Mkt Cap10.57B	Tradable Cap10.57B	Total Shares969.00M
T/O21.98M	T/O Rate0.21%	Tradable Shares969.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"09966","market":"HK","secType":"STK","nameCN":"ALPHAMAB-B","latestPrice":10.91,"timestamp":1766131686008,"preClose":10.67,"halted":0,"volume":1998200,"delay":0,"floatShares":969000000,"shares":969000000,"eps":0.1913017452085068,"marketStatus":"Market Closed","change":0.24,"latestTime":"12-19 16:08:06","open":10.7,"high":11.2,"low":10.45,"amount":21977490,"amplitude":0.070291,"askPrice":10.93,"askSize":61000,"bidPrice":10.91,"bidSize":14000,"shortable":3,"etf":0,"ttmEps":0.26148020916822945,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1766367000000},"marketStatusCode":7,"adr":0,"listingDate":1576080000000,"exchange":"SEHK","adjPreClose":10.67,"openAndCloseTimeList":[[1766107800000,1766116800000],[1766120400000,1766131200000]],"volumeRatio":1.6955926641294934,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09966","defaultTab":"news","newsList":[{"id":"2592149879","title":"Alphamab Oncology (SEHK:9966): Assessing Valuation After New Breakthrough Therapy and IND Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2592149879","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592149879?lang=en_us&edition=fundamental","pubTime":"2025-12-20 21:13","pubTimestamp":1766236431,"startTime":"0","endTime":"0","summary":"Alphamab Oncology (SEHK:9966) just cleared two important regulatory hurdles, with US breakthrough therapy status for JSKN003 and China IND acceptance for JSKN027, tightening investor focus on how these ADC assets might reshape its valuation.\nSee our latest analysis for Alphamab Oncology.\nThe latest catalysts come after a powerful run, with the share price last closing at HK$10.91 and a year to date share price return of 218.08 percent. The 5 year total shareholder return of negative 27.56...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9966/alphamab-oncology-shares/news/alphamab-oncology-sehk9966-assessing-valuation-after-new-bre","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9966/alphamab-oncology-shares/news/alphamab-oncology-sehk9966-assessing-valuation-after-new-bre","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1574","IND","DCF","BK1161","09966"],"gpt_icon":0},{"id":"2592932121","title":"What Alphamab Oncology (SEHK:9966)'s IND Acceptance for JSKN027 Bispecific ADC Means For Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2592932121","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592932121?lang=en_us&edition=fundamental","pubTime":"2025-12-19 19:18","pubTimestamp":1766143124,"startTime":"0","endTime":"0","summary":"Alphamab Oncology recently reported that the Center for Drug Evaluation of China’s NMPA has accepted its IND application for JSKN027, an independently developed bispecific antibody-drug conjugate targeting PD-L1 and VEGFR2, paving the way for a Phase I trial in advanced solid tumors.\nThis milestone highlights Alphamab Oncology’s push into next-generation bispecific ADCs that combine immune checkpoint blockade and anti-angiogenic mechanisms within a single molecule.\nWe’ll now examine how the...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9966/alphamab-oncology-shares/news/what-alphamab-oncology-sehk9966s-ind-acceptance-for-jskn027","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9966/alphamab-oncology-shares/news/what-alphamab-oncology-sehk9966s-ind-acceptance-for-jskn027","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["IND","BK1574","BK4231","ADC","BK4080","09966","BK1161"],"gpt_icon":0},{"id":"2592924931","title":"BUZZ-Alphamab Oncology jumps on progress of ovarian cancer drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2592924931","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592924931?lang=en_us&edition=fundamental","pubTime":"2025-12-18 13:37","pubTimestamp":1766036264,"startTime":"0","endTime":"0","summary":"BUZZ-Alphamab Oncology jumps on progress of ovarian cancer drug** Alphamab Oncology 9966.HK rises 7.1% to HK$10.96; set for biggest one-day pct gain since October 2** Stock hits highest since December 15 after three straight sessions of fall** Company says its JSKN003 has been granted breakthrough therapy designation  by U.S. FDA to treat adults with advanced or metastatic platinum-resistant recurrent epithelial ovarian cancer** Adds, \"The grant of this BTD further demonstrates the international regulatory community's confidence in JSKN003's clinical potential and its importance as a novel therapeutic candidate\"** Grant of BTD based on pooled analysis of phase I clinical study in Australia and phase I/II clinical study in China** YTD, stock surges 207.1%  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nL1N3XO05J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09966","BK1161","BK1574"],"gpt_icon":0},{"id":"2592373929","title":"Alphamab Oncology - FDA Grants Breakthrough Therapy Designation to Jskn003 for Proc","url":"https://stock-news.laohu8.com/highlight/detail?id=2592373929","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592373929?lang=en_us&edition=fundamental","pubTime":"2025-12-18 12:01","pubTimestamp":1766030463,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nFWN3XN1I1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["09966","BK1161","BK1574"],"gpt_icon":0},{"id":"2592991610","title":"Alphamab Oncology's Application for Tumor Drug Accepted by Chinese Regulator","url":"https://stock-news.laohu8.com/highlight/detail?id=2592991610","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592991610?lang=en_us&edition=fundamental","pubTime":"2025-12-17 19:11","pubTimestamp":1765969904,"startTime":"0","endTime":"0","summary":"Alphamab Oncology's  investigational new drug application for JSKN027 was accepted by China's National Medical Products Administration, a Wednesday Hong Kong bourse filing said.The firm plans to initiate a phase I clinical study of JSKN027 for the treatment of advanced malignant solid tumors to evaluate its safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1574","09966","BK1161"],"gpt_icon":0},{"id":"1186071414","title":"ALPHAMAB-B (09966): JSKN027 IND Application Officially Accepted by CDE","url":"https://stock-news.laohu8.com/highlight/detail?id=1186071414","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1186071414?lang=en_us&edition=fundamental","pubTime":"2025-12-17 18:18","pubTimestamp":1765966713,"startTime":"0","endTime":"0","summary":"ALPHAMAB-B (09966) announced that the Investigational New Drug (IND) application for its self-developed PD-L1/VEGFR2 bispecific antibody-drug conjugate (ADC) JSKN027 has been officially accepted by...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4017","IND","LU1223082196.USD","BK1574","LU1223082519.USD","09966","BK1161","LU1223083913.SGD","CDE"],"gpt_icon":0},{"id":"2592996320","title":"Alphamab Oncology IND Application for JSKN027 Accepted by Chinese Regulator","url":"https://stock-news.laohu8.com/highlight/detail?id=2592996320","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592996320?lang=en_us&edition=fundamental","pubTime":"2025-12-17 18:04","pubTimestamp":1765965861,"startTime":"0","endTime":"0","summary":"Alphamab Oncology announced that its Investigational New Drug  application for JSKN027, an independently developed PD-L1/VEGFR2 bispecific antibody-drug conjugate, has been officially accepted by the Center for Drug Evaluation  of the National Medical Products Administration of China. The company plans to initiate a phase I clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of JSKN027 in patients with advanced malignant solid tumors.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alphamab Oncology published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on December 17, 2025","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nNDLzsP3M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09966","BK1574","BK1161"],"gpt_icon":0},{"id":"2592799634","title":"Alphamab Oncology - Ind Application for Jskn027 Accepted by Cde","url":"https://stock-news.laohu8.com/highlight/detail?id=2592799634","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592799634?lang=en_us&edition=fundamental","pubTime":"2025-12-17 18:04","pubTimestamp":1765965855,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nFWN3XM0WP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","BK1574","09966"],"gpt_icon":0},{"id":"1167152262","title":"Alphamab Oncology (09966) Announces Monthly Return on Movements in Securities for November 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=1167152262","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1167152262?lang=en_us&edition=fundamental","pubTime":"2025-12-04 17:15","pubTimestamp":1764839733,"startTime":"0","endTime":"0","summary":"Alphamab Oncology (09966) submitted a monthly return, dated December 4, 2025, detailing its authorized and issued share movements for November 2025. The authorized share capital remained at...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09966"],"gpt_icon":0},{"id":"1127489049","title":"HK Movers | Biotech Stocks Rise. Ascletis up 9%; Antengene up over 5%; Remegen, Laekna, Akeso, Hua Medicine up About 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=1127489049","media":"Tiger Newspress","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1127489049?lang=en_us&edition=fundamental","pubTime":"2025-12-04 10:26","pubTimestamp":1764815206,"startTime":"0","endTime":"0","summary":"Biotech stocks jumped in Hong Kong. Ascletis up 9%; Antengene up over 5%; Remegen, Laekna, Akeso, Hua Medicine up about 4%; Zai Lab up over 3%.","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"2c8d9a47d2e27ece6292940208c30d20","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02359","06606","09606","01672","02268","09966","03759","03347","02137","09688","09995","02269","06978"],"gpt_icon":0},{"id":"1109808809","title":"HK Movers | Biotech Stocks Fall. Ascletis-B down 11%; Hua Medicine-B, Mabpharm-B down about 7%; Antengene-B down 5%; Ascentage-B down 4%.","url":"https://stock-news.laohu8.com/highlight/detail?id=1109808809","media":"Tiger Newspress","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1109808809?lang=en_us&edition=fundamental","pubTime":"2025-12-03 13:18","pubTimestamp":1764739138,"startTime":"0","endTime":"0","summary":"Bitech stocks fell in Hong Kong. Ascletis-B down 11%; Hua Medicine-B, Mabpharm-B down about 7%; Antengene-B down 5%; Ascentage-B down 4%.","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"2c8d9a47d2e27ece6292940208c30d20","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09995","02359","09688","02268","01672","02137","09606","09966","03347","03759","02269","06978","06606"],"gpt_icon":0},{"id":"1183993282","title":"ALPHAMAB-B (09966) Repurchases 236,000 Shares for HK$2.457 Million on December 1","url":"https://stock-news.laohu8.com/highlight/detail?id=1183993282","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1183993282?lang=en_us&edition=fundamental","pubTime":"2025-12-01 20:30","pubTimestamp":1764592244,"startTime":"0","endTime":"0","summary":"ALPHAMAB-B (09966) announced that it repurchased 236,000 shares on December 1, 2025, for a total consideration of HK$2.457 million.","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","09966","BK1161"],"gpt_icon":0},{"id":"2588722423","title":"Alphamab Oncology Files HKEX Disclosure on Repurchase of 236,000 Shares for HKD 2.46 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2588722423","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588722423?lang=en_us&edition=fundamental","pubTime":"2025-12-01 20:23","pubTimestamp":1764591836,"startTime":"0","endTime":"0","summary":"Alphamab Oncology has filed a next day disclosure return with the Hong Kong Stock Exchange, reporting the repurchase of 236,000 shares at a total aggregate price of HKD 2,457,270. The repurchased shares will be held as treasury shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alphamab Oncology published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on December 01, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nNDL9sNgch:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","09966","BK1161"],"gpt_icon":0},{"id":"1172808001","title":"Alphamab Oncology (09966) Reports Changes in Issued Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=1172808001","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1172808001?lang=en_us&edition=fundamental","pubTime":"2025-11-27 22:43","pubTimestamp":1764254585,"startTime":"0","endTime":"0","summary":"Alphamab Oncology (09966) announced share capital changes effective 27 November 2025. Prior to these changes, 969,164,697 ordinary shares were in issue, with 4,983,000 recorded as treasury shares....","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09966"],"gpt_icon":0},{"id":"1156670231","title":"ALPHAMAB-B (09966) Issues 146,000 Shares Due to Exercise of Options","url":"https://stock-news.laohu8.com/highlight/detail?id=1156670231","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156670231?lang=en_us&edition=fundamental","pubTime":"2025-11-27 22:28","pubTimestamp":1764253692,"startTime":"0","endTime":"0","summary":"ALPHAMAB-B (09966) announced that on November 27, 2025, it issued 146,000 shares as a result of the exercise of options.","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09966","BK1161","BK1574"],"gpt_icon":0},{"id":"1190899235","title":"HK Pharma Shares Gained. CSPC Pharma Up 7%; 3SBio Up 6%; Remegen Up 4%; Sino Biopharm, Junshi Bio And Hengrui Pharma Up 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=1190899235","media":"Tiger Newspress","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1190899235?lang=en_us&edition=fundamental","pubTime":"2025-11-26 09:43","pubTimestamp":1764121396,"startTime":"0","endTime":"0","summary":"HK Pharma Shares Gained. CSPC Pharma Up 7%; 3SBio Up 6%; Remegen Up 4%; Sino Biopharm, Junshi Bio And Hengrui Pharma Up 3%.","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"cdafad46000135333541ff3f84174d8f","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268","01093","06606","09688","01672","03759","02137","01530","09606","09995","09966","02359","03347","02269","06978"],"gpt_icon":0},{"id":"1102802251","title":"HK Movers｜Biotech Shares Gained. 3SBio And Hengrui Pharma Up 5%; Tigermed Up 3%; SKB Bio, JW Therap, Remegen And Wuxi XDC Up 2%","url":"https://stock-news.laohu8.com/highlight/detail?id=1102802251","media":"Tiger Newspress","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1102802251?lang=en_us&edition=fundamental","pubTime":"2025-11-24 10:04","pubTimestamp":1763949852,"startTime":"0","endTime":"0","summary":"HK's Biotech Shares Gained. 3SBio and Hengrui Pharma up 5%; Tigermed up 3%; SKB Bio, JW Therap, Remegen and Wuxi XDC up 2%.","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03347","01672","01276","02359","02269","09606","01530","09688","02137","02268","09995","09966","03759","06978","06606"],"gpt_icon":0},{"id":"1172633693","title":"Hong Kong Stock Buyback Report | November 18","url":"https://stock-news.laohu8.com/highlight/detail?id=1172633693","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1172633693?lang=en_us&edition=fundamental","pubTime":"2025-11-18 09:12","pubTimestamp":1763428350,"startTime":"0","endTime":"0","summary":"Several Hong Kong-listed companies conducted share buybacks on November 17, 2025. Among them, China Feihe (06186) recorded the highest buyback amount, repurchasing 10.811 million shares for...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1229","LU0385154629.USD","BK1226","IE0032834883.USD","LU0359202008.SGD","LU1224709979.USD","00732","BK1516","BK1562","LU0211977185.USD","08128","LU0651947912.USD","BK1222","LU0244354667.USD","LU0588546209.SGD","02416","02319","LU1048596156.SGD","BK1518","SG9999011746.SGD","BK1189","BK1618","LU2045819591.USD","LU0359201612.USD","LU1048588211.SGD","BK1606","HK0000306701.USD","BK1521","00777","02869","06186","BK1253","06826","LU1023057109.AUD","BK1225","LU1515016050.SGD","LU0293314216.USD","00366","09869","BK1151","LU0320764755.SGD","01681","BK1103","02142","SG9999001440.SGD","00975","BK1526","BK1507","06868","BK1589","BK1553","LU0228367735.SGD","LU0029875118.USD","BK1531","02598","BK1237","LU1051768304.USD","00103","LU0228659784.USD","LU0163747925.USD","IE00B97KM107.HKD","LU2097828474.EUR","LU0181495838.USD","LU0348788117.USD","LU1102505929.USD","LU0140636845.USD","LU1188198961.HKD","IE00B067MR52.USD","LU1831875114.USD","LU1439103000.SGD","00909","02509","01586","IE0031814852.USD","02251","01919","LU1282651048.USD","BK1155","02038","LU0737861699.HKD","BK1506","LU0650527681.SGD","BK1258","LU0828237940.HKD","02469","BK1607","BK1508","09959","LU0173614495.USD","BK1117","LU0259732245.USD","LU2097828631.EUR","BK1519","LU0048580855.USD","SG9999002828.SGD","BK1542","HK0000320223.HKD","IE00B031J352.USD","IE00B031HY20.USD","BK1233","BK1167","01931","BK1191","LU1769817179.HKD","02039","BK1504","01588","02171","BK1161","BK1583","LU0821914370.USD","00386","BK1599","BK1116","BK1593","BK1104","LU0651946864.USD","BK1535","BK1500","BK1170","LU1769817096.USD","LU2097828714.EUR","BK1228","BK1528","BK1505","IE00B0169L03.USD","LU2125910500.SGD","HK0000320264.USD","BK1183","BK1574","LU1102505762.USD","LU0328353924.USD","BK1197","BK1209","LU0463099449.HKD","09663","IE0008369823.USD","LU0287142896.SGD","BK1538","LU2097828557.USD","BK1619","BK1517","HK0000306685.HKD","LU0326950275.SGD","01519","IE00B29SXG58.USD","LU1051769294.HKD","00947","BK1149","BK1585","02392","BK1597","00418","BK1575","BK1158","LU0251143458.SGD","BK1148","LU0672654166.SGD","09966","LU0823426480.USD","LU0471298777.SGD","LU0370786039.SGD","01066","LU0106959298.USD","08188","LU0307460666.USD","BK1109","LU0359201885.HKD","LU0348805143.USD","LU0594300419.USD","LU0823426308.USD","BK1135","LU0315179316.USD","LU0128522157.USD","BK1202","BK1587","00383","IE0009570106.USD","LU0543330483.HKD","LU2097828805.USD","IE0008368742.USD","LU0072462343.USD"],"gpt_icon":0},{"id":"2584625292","title":"Alphamab Oncology Files Next Day Disclosure Return to HKEX for Repurchase of 350,000 Shares at HKD 9.77 Each","url":"https://stock-news.laohu8.com/highlight/detail?id=2584625292","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584625292?lang=en_us&edition=fundamental","pubTime":"2025-11-17 21:12","pubTimestamp":1763385145,"startTime":"0","endTime":"0","summary":"Alphamab Oncology has filed a Next Day Disclosure Return with the Hong Kong Stock Exchange, reporting the repurchase of 350,000 shares at an average price of HKD 9.7708 per share.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alphamab Oncology published the original content used to generate this news brief on November 17, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nNDL3FF2zp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","09966","BK1161"],"gpt_icon":0},{"id":"1147887032","title":"ALPHAMAB-B (09966) Repurchases 350,000 Shares for HK$3.4198 Million on November 17","url":"https://stock-news.laohu8.com/highlight/detail?id=1147887032","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1147887032?lang=en_us&edition=fundamental","pubTime":"2025-11-17 20:48","pubTimestamp":1763383690,"startTime":"0","endTime":"0","summary":"ALPHAMAB-B (09966) announced that it repurchased 350,000 shares on November 17, 2025, for a total consideration of HK$3.4198 million.","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1574","09966"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.alphamab.com","stockEarnings":[{"period":"1week","weight":0.0177},{"period":"1month","weight":0.0696},{"period":"3month","weight":-0.0715},{"period":"6month","weight":0.6068},{"period":"1year","weight":2.1083},{"period":"ytd","weight":2.1171}],"compareEarnings":[{"period":"1week","weight":-0.011},{"period":"1month","weight":-0.0054},{"period":"3month","weight":-0.0322},{"period":"6month","weight":0.0918},{"period":"1year","weight":0.3006},{"period":"ytd","weight":0.2807}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Alphamab Oncology is an investment holding company principally engaged in research and development, manufacturing and commercialisation of biologics of oncology. The Company’s highly differentiated in-house pipeline consists of ADCs, monoclonal antibodies and bispecific antibodies in staggered development status in oncology. The Company’s drug candidates include KN046 (PD-L1/CTLA-4 bispecific antibody), KN026 (HER2/HER2 bispecific antibody), KN035 (SubQ PD-L1), JSKN003 (HER2 biparatopic ADC), and others, used for indications such as 1L sq NSCLC, 1L HER2+ BC, advanced solid tumors, and HER2-expressing solid tumors.","yearOnYearQuotes":[{"month":1,"riseRate":0.166667,"avgChangeRate":-0.121729},{"month":2,"riseRate":0.666667,"avgChangeRate":0.22886},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.028638},{"month":4,"riseRate":0.833333,"avgChangeRate":0.061128},{"month":5,"riseRate":0.5,"avgChangeRate":-0.016858},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.029877},{"month":7,"riseRate":0.333333,"avgChangeRate":0.059359},{"month":8,"riseRate":0.333333,"avgChangeRate":0.022561},{"month":9,"riseRate":0.333333,"avgChangeRate":0.158319},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.030396},{"month":11,"riseRate":0.5,"avgChangeRate":0.042537},{"month":12,"riseRate":0.666667,"avgChangeRate":-0.000458}],"exchange":"SEHK","name":"ALPHAMAB-B","nameEN":"ALPHAMAB-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ALPHAMAB-B(09966),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ALPHAMAB-B(09966) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ALPHAMAB-B,09966,ALPHAMAB-B股票,ALPHAMAB-B股票老虎,ALPHAMAB-B股票老虎国际,ALPHAMAB-B行情,ALPHAMAB-B股票行情,ALPHAMAB-B股价,ALPHAMAB-B股市,ALPHAMAB-B股票价格,ALPHAMAB-B股票交易,ALPHAMAB-B股票购买,ALPHAMAB-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ALPHAMAB-B(09966),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ALPHAMAB-B(09966) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}